Sarepta Therapeutics (SRPT) Tuesday reported first-quarter net loss of $447.5 million or $4.60 per share, compared to net income of $36.1 million or $0.37 per share in the same period last year.
Excluding items, Sarepta Therapeutics reported adjusted loss of $332.5 million or $3.42 per share for the period.
Research and development expenses were $773.4 million for the three months ended March 31, 2025, as compared to $200.4 million for the same period of 2024, an increase of $573.0 million. The increase in research and development expenses primarily reflects an increase in up-front and milestone expense associated with the licensing and collaboration agreement and stock purchase agreement with Arrowhead, partially offset by a decrease in clinical trial expenses primarily due to the discontinuation of the PPMO programs in 2024.
Revenues for the quarter rose to $744.9 million from $413.5 million in the same period last year.
Looking forward, the company expects net product revenues of $2.30 billion to $2.60 billion, down from prior estimate of $2.90 billion to $3.10 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.